PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision repair, may correlate with clinical response to platinum agents. We found that most primary lung tumor specimens demonstrated a stronger protein expression of poly (adenosine diphosphate ribose) polymerases 1 (PARP1) than their normal counterparts. Therefore, we hypothesized that combining PARP inhibition with platinum compounds may be an approach to improve platinum-based therapy for NSCLC. Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells. Moreover, small interfering RNA knockdown of ERCC1 in A549 and H157 cells increased their sensitivities to both cisplatin and olaparib in a synergistic manner in our model. Furthermore, mechanistic studies indicated that combined PARP inhibitor and cisplatin could lead to sustained DNA double-strand breaks, prolonged G2/M cell cycle arrest with distinct activation of checkpoint kinase 1 signaling and more pronounced apoptosis preferentially in lung cancer cells with low ERCC1 expression. Collectively, these data suggest that there is a synergistic relationship between PARP inhibition and low ERCC1 expression in NSCLC that could be exploited for novel therapeutic approaches in lung cancer therapy based on tumor ERCC1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188 · cited 1×
“Clonogenic survival was assayed as described previously (24).”
MethodCellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801 · cited 1×
“Platinum–DNA adducts are removed mainly by the nucleotide excision repair (NER) pathway (3).”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · cited 1×
“Phase II clinical trials further demonstrated the efficacy and safety of olaparib in BRCA-associated breast and ovarian cancers (17,18).”
BackgroundOlaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883 · cited 1×
“Moreover, a recent randomized phase II study demonstrated that maintenance therapy with olaparib could provide a significant improvement in progression-free survival in patients with platinumsensitive relapsed serous ovarian cancer (19).”
BackgroundDNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727 · cited 1×
“When evaluated in clinical trials, the International Adjuvant Lung Cancer Trial demonstrated that only ERCC1 low/negative but not ERCC1 high/positive tumors had a survival benefit from cisplatin-based adjuvant chemotherapy (7).”
MethodTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · cited 1×
“Inhibition of poly (adenosine diphosphate ribose) polymerases (PARPs), key components of base excision repair, have been shown to enhance platinum sensitivity in BRCA-associated breast and ovarian cancers (11,12).”
BackgroundThe ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276 · cited 2×
“We then examined the ATR-CHK1 and ATM-CHK2 pathways, which are two principal mechanisms activated by DNA damage and their activation is involved in regulating cell cycle arrest in late G1, intra-S and G2 phases (32).”
BackgroundMethod
Research works printed but not linked: 3
- KIRSCHNER, 2010, Anticancer Research, 30, 3223
- Selvakumaran, 2003, Cancer Research, 63, 1311
- Sorenson, 1988, Cancer Research, 48, 6703
Cited by
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Di Agostino, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 201
“Combination strategies with olaparib and chemotherapeutic agents have shown to be effective in ERCC1 or PTEN-deficient lung cancer cells, showing that other deficiencies in DNA-repair pathways frequently occurring in NSCLC might have an impact on the response to olaparib treatment, and consequently also on this combin…”
BackgroundTherapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
“Early preclinical data has found PARP inhibition sensitized SCLC to cisplatin therapy (67).”
BackgroundDrugging the Cancers Addicted to DNA Repair
Nickoloff, J. A., Jones, D., Lee, S.-H., Williamson, E. A., & Hromas, R. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx059 · Cited by 159
The role of DNA repair pathways in cisplatin resistant lung cancer
O’Grady, S., Finn, S. P., Cuffe, S. D., Richard, D. J., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.003 · Cited by 161
ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
Mohni, K. N., Kavanaugh, G. M., & Cortez, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3229 · Cited by 150
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 150
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 129
“ERCC1 low expression in the NSCLC model is sufficient to determine a synergistic effect with PARP inhibition [146, 147].”
BackgroundAdvances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
O'Sullivan, C. C., Moon, D. H., Kohn, E. C., & Lee, J. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00042 · Cited by 116
Postel-Vinay, S. C., Bajrami, I., Friboulet, L., Elliott, R. J. R., Fontebasso, Y., Dorvault, N., Olaussen, K. A., André, F., Soria, J., Lord, C. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.311 · Cited by 114
Cheng, H., Zhang, Z., Rodriguez-Barrueco, R., Borczuk, A., Liu, H., Yu, J., Silva, J. M., Cheng, S. K., Perez-Soler, R., & Halmos, B. (2016) · Oncotarget · doi:10.18632/oncotarget.6721 · Cited by 92
“Cisplatin and erlotinib were added for 3 days [5].”
BackgroundSelf-citationMiddleton, M. R., Friedlander, P. A., Hamid, O., DAUD, A. I., Plummer, R., Falotico, N., Chyla, B., Jiang, F., McKeegan, E. M., Mostafa, N. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv308 · Cited by 96
Owonikoko, T. K., Zhang, G., Deng, X., Rossi, M. R., Switchenko, J. M., Doho, G., Chen, Z., Kim, S., Strychor, S., Christner, S. M., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.317 · Cited by 99
“prior reports showing that a higher concentration of veliparib was required for in vitro modeling of therapeutic effect [36, 37].”
BackgroundResultPrasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13232-3 · Cited by 84
Yarchoan, M., Myzak, M. C., Johnson, B. A., De Jesus-Acosta, A., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 77
“Although PARP inhibitors and DNA damaging agents are a rational drug combination with encouraging signs of activity in preclinical models [10, 20, 21], future clinical trials of combination therapies that include PARP inhibitor should be vigilant about monitoring for hematologic toxicity.”
BackgroundAberrations in DNA repair pathways in cancer and therapeutic significances
Motegi, A., Masutani, M., Yoshioka, K., & Bessho, T. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.005 · Cited by 79
Zarogoulidis, P., Petanidis, S., Kioseoglou, E., Domvri, K., Anestakis, D., & Zarogoulidis, P. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.04.009 · Cited by 74
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Concannon, K., Morris, B. B., Gay, C. M., & Byers, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.031 · Cited by 81
Duan, S., Tsai, Y., Keng, P., Chen, Y., Lee, S. O., & Chen, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4753 · Cited by 76
“Recently it was also reported that hyperactivation of PARP was involved in cisplatin resistance in lung cancer cells [7] and inhibition of PARP could selectively increase the cellular sensitivity to cisplatin [8].”
BackgroundPARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair
Choi, E.-B., Yang, A.-Y., Kim, S. C., Lee, J., Choi, J. K., Choi, C., & Kim, M. Y. (2016) · Oncogene · doi:10.1038/onc.2016.3 · Cited by 62
Deben, C., Lardon, F., Wouters, A., de Beeck, K. O., den Bossche, J. V., Jacobs, J., Steen, N. V. D., Peeters, M., Rolfo, C. D., Deschoolmeester, V., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.017 · Cited by 64
Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
Lodovichi, S., Cervelli, T., Pellicioli, A., & Galli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186684 · Cited by 59
Dutta, A., Yang, C., Sengupta, S., MITRA, S. P., & Hegde, M. L. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1820-z · Cited by 58
“More recently, PARP1 has been shown to have high expression in non-small cell lung cancer cell lines resistant to cisplatin, compared to those cisplatin-susceptible ones, suggesting its correlation with tumor resistance to therapy [170, 171].”
BackgroundNew therapeutic perspectives in CCDC 6 deficient lung cancer cells
Morra, F., Luise, C., Visconti, R., Staibano, S., Merolla, F., Ilardi, G., Guggino, G., Paladino, S., Sarnataro, D., Franco, R., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29263 · Cited by 57
“Nevertheless, treatment with inhibitors of the DNA repair enzymes, like the PARP inhibitors, restores the sensitivity to DNA damage inducers.(11,12,39,40) H460 cells, depleted of CCDC6, are quite resistant to cisplatinum, and the PARP inhibitor olaparib reestablishes cisplatinum sensitivity, by acting in synergy with…”
BackgroundLiu, H., Li, W., Yu, X., Gao, F., Duan, Z., Ma, X., Tan, S., Yuan, Y., Liu, L., Wang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10841 · Cited by 55
“Platinum compounds are the foundation of chemotherapy regimens for NSCLC despite poor response rates and limited response duration [47].”
BackgroundDouble-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
Lu, Y., Liu, Y., Pang, Y. K., Pacák, K., & Yang, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.006 · Cited by 54
“Combination treatmentwith olaparib also improves the therapeutic effect of cisplatin in non-small cell lung cancer cells (Cheng et al., 2013; Michels et al., 2013).”
BackgroundCombining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Yusoh, N. A., Ahmad, H., & Gill, M. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000391 · Cited by 57
Comparative molecular profiling of HPV‐induced squamous cell carcinomas
Koncar, R. F., Feldman, R. A., Bahassi, E. M., & Sadraei, N. H. (2017) · Cancer Medicine · doi:10.1002/cam4.1108 · Cited by 50
“In vitro work suggests that the addition of a PARP inhibitor to a platinumbased treatment strategy may be beneficial when tumors have low ERCC1 expression [52].”
BackgroundCisplatin in the era of PARP inhibitors and immunotherapy
Duan, M., Leng, S., & Mao, P. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108642 · Cited by 54
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 48
Mesquita, K. A., Alabdullah, M., Griffin, M., Toss, M. S., Fatah, T. M. A. A., Alblihy, A., Moseley, P. M., Chan, S. Y. T., Rakha, E. A., & Madhusudan, S. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.02.014 · Cited by 45
Genetic alterations and their therapeutic implications in epithelial ovarian cancer
Lapke, N., Chen, C., Chang, T., Chao, A., Lu, Y., Lai, C., Tan, K. T., Chen, H., Lu, H., & Chen, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08233-5 · Cited by 43
Swisher, E. M., Aghajanian, C. A., O’Malley, D. M., Fleming, G. F., Kaufmann, S. H., Levine, D. A., Birrer, M. J., Moore, K. N., Spirtos, N. M., Shahin, M. S., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.12.003 · Cited by 45
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat
To, K. K. W., Tong, W. S., & Fu, L. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.019 · Cited by 40
Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis
Neelakantan, D., Dogra, S., Devapatla, B. K., Jaiprasart, P., Mukashyaka, M. C., Janknecht, R., Dwivedi, S. K. D., Bhattacharya, R., Husain, S., Ding, K., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0989 · Cited by 37
“There have been reports (26, 27) that show correlations between increased PARP levels and increased chemoresistance, and studies to elucidate this interplay are ongoing.”
BackgroundHu, X., Feng, J., Pham, T., Ma, H.-Y., Ma, M., Song, R., Shen, W., Xiong, F., Zhang, X., Ye, W., et al. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.012 · Cited by 37
Xu, K., Chen, Z., Cui, Y. W., Qin, C., He, Y., & Song, X. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89154 · Cited by 38
“Cheng et al 22 found that there was a significant increase in the G 2 /M population in ERCC1-low HCC827 and PC9 cells induced by either cisplatin or olaparib, and that the combination of cisplatin and olaparib led to an even more prominent G 2 /M arrest than either agent alone.”
Wéra, A.-C., Lobbens, A., Stoyanov, M., Lucas, S., & Michiels, C. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1632640 · Cited by 35
Wang, Q., Xiong, J., Qiu, D., Zhao, X. B., Yan, D., Xu, W., Wang, Z., Chen, Q., Panday, S., Li, A., et al. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.08.001 · Cited by 34
“Therefore, the formation of PAR polymers could serve as an indicator of PARP1 activity (Cheng et al. , 2013).”
BackgroundCai, Y., Yan, X., Zhang, G., Zhao, W., & Jiao, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3620 · Cited by 33
“First, we transfected two individual siRNAs that had been reported previously [21, 22] into PC-14, H1299 and H2172 cells, which are all ERCC1High cell lines.”
Bound, N. T., Vandenberg, C. J., Kartikasari, A. E. R., Plebanski, M., & Scott, C. L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886170 · Cited by 33
“The use of PARPi in combination with platinum chemotherapy has the potential to sensitise tumour cells to DNA-damaging agents and potentially the anti-tumour immune response (Nguewa et al., 2006; Cheng et al., 2013).”
BackgroundPoly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers
Przybyciński, J., Nalewajska, M., Marchelek‐Myśliwiec, M., Dziedziejko, V., & Pawlik, A. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1654458 · Cited by 30
“Olaparib in combination with cisplatin increases the effectiveness of the treatment of non-small cell lung cancer cells [57].”
BackgroundCombination of PARP inhibitor and temozolomide to suppress chordoma progression
Cao, X., Lu, Y., Liu, Y., Zhou, Y., Song, H., Zhang, W., Davis, D. L., Cui, J., Hao, S., Jung, J., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01802-z · Cited by 29
Chen, H., Zeng, X., Gao, C., Ming, P., Zhang, J., Guo, C., Zhou, L., Lu, Y., Wang, L., Huang, L., et al. (2015) · Scientific Reports · doi:10.1038/srep10893 · Cited by 28
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
Avila, S., Núñez, G. S., García‐Fernández, L., & Galmarini, C. M. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.4.329 · Cited by 26
“A clear example is the increased sensitivity of XPF/ERCC1-deficient cells to olaparib [23].”
BackgroundWęsierska‐Gądek, J., Mauritz, M., Mitulović, G., & Cupo, M. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25229 · Cited by 27
“Gradually, this new therapeutic strategy has been extended to other cancer types (e. g., ovarian and prostate cancer) [Cheng et al., 2013], [Banerjee et al., 2010], [Postel-Vinay et al., 2013], [Tentori et al., 2014] not only with BRCA mutations, but also with mutations in other genes involved in…”
BackgroundMapping genetic interactions in cancer: a road to rational combination therapies
Tutuncuoglu, B., & Krogan, N. J. (2019) · Genome Medicine · doi:10.1186/s13073-019-0680-4 · Cited by 25
Clarke, J. M., Patel, J. D., Robert, F., Kio, E. A., Thara, E., Camidge, D. R., Dunbar, M., Nuthalapati, S., Dinh, M. H., & Bach, B. A. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.004 · Cited by 25
XIONG, T., Wei, H., CHEN, X., & Xiao, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2726 · Cited by 25
Elemental bioimaging of Cisplatin inCaenorhabditis elegansby LA-ICP-MS
Crone, B., Aschner, M., Schwerdtle, T., Kärst, U., & Bornhorst, J. (2015) · Metallomics · doi:10.1039/c5mt00096c · Cited by 24
Menon, V., Peterson, E. J., Valerie, K. C., Farrell, N. P., & Povirk, L. F. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.012 · Cited by 24
“Considering these promising early findings and the potential for clinical combinations of platinum drugs with DNA-repair modifying agents such as PARP inhibitors [35] it was important to examine whether the cell signaling responses elicited by BBR3610DACH were similar to those of other platinum-based compounds, both m…”
ResultWan, Q., Shen, Y., Zhao, H., Wang, B., Zhao, L., Zhang, Y., Bu, X., Wan, M., & Shen, C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27703 · Cited by 23
Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review
Mao, X., Lee, N. K., Saad, S. E., & Fong, I. L. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-742 · Cited by 24
“Mechanistic studies indicated that PARP inhibitor plus cisplatin could lead to sustained DSBs, prolonged G2/M cell cycle arrest and more pronounced apoptosis preferentially in NSCLC cells with low ERCC1 expression (106), or PTEN deficient (107).”
BackgroundThe molecular landscape of pancreatic ductal adenocarcinoma
Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · Pancreatology · doi:10.1016/j.pan.2022.07.010 · Cited by 24
DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets
Doherty, R. E., & Madhusudan, S. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115581581 · Cited by 24
“In comparison, ERCC1-high cells did not exhibit the same cytotoxic effects following treatment.(128) A recent study has demonstrated that treatment of MRE11-deficient endometrial cancer cell lines with the PARP inhibitor BMN673 (BioMarin) results in significant cell death in vitro compared with MRE11-proficient cell l…”
BackgroundPARP inhibitors as precision medicine for cancer treatment
Du, Y., Yamaguchi, H., Hsu, J. L., & Hung, M. (2017) · National Science Review · doi:10.1093/nsr/nwx027 · Cited by 20
Shen, H.-Y., Tang, H., Zheng, Y., Feng, J., Dong, B., & Chen, X. (2022) · Journal of Oncology · doi:10.1155/2022/2800488 · Cited by 18
Yusoh, N. A., Chia, S. L., Saad, N., Ahmad, H., & Gill, M. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-28454-x · Cited by 18
Song, L., McNeil, E. M., Ritchie, A., Astell, K. R., Gourley, C., & Melton, D. W. (2017) · BMC Cancer · doi:10.1186/s12885-017-3864-6 · Cited by 21
“However, when we examined the key HRR protein, RAD51, we found that levels unexpectedly decreased by at least 65% in all five melanoma cell lines examined over a 3-day exposure to cisplatin, while levels in an ovarian cancer and a fibroblast cell line increased over the same period, as reported previously for lung can…”
Backgroundvan der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui‐Roelvink, M., Lolkema, M. P., de Jonge, M. J. A., van der Biessen, D. A. J., Brunetto, A. T., Arkenau, H., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00856-7 · Cited by 17
Liu, H., Daylan, A. E. C., Yang, J., Tanwar, A., Borczuk, A., Zhang, D., Chau, V., Li, S., Ge, X., Halmos, B., et al. (2024) · Cancers · doi:10.3390/cancers16162805 · Cited by 15
“Immunohistochemistry: As previously described [33,34], formalin-fixed primary lung tumor tissue sections were deparaffinized and subjected to antigen retrieval treatment with sodium citrate (10 mM, pH 6.0) after rehydration.”
MethodInfluentialSelf-citationJuncheng, P., Joseph, A., Lafarge, A., Martins, I., Obrist, F., Pol, J. G., Saavedra, E., Li, S., Sauvat, A., Cerrato, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004280 · Cited by 15
Chang, J., Chen, C.-C., Wu, Y.-Y., Che, T.-F., Huang, Y.-S., Yeh, K.-T., Shieh, G. S., & Yang, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12046 · Cited by 14
“Several reports have also found that the synthetic lethality was enhanced via combinations of PARP inhibitors and platinum-based drugs in breast cancer [33] and lung cancer [34, 35].”
BackgroundVanderWeele, D. J., Paner, G. P., Fleming, G. F., & Szmulewitz, R. Z. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00169 · Cited by 13
DNA Repair Pathways and their Therapeutic Potential in Lung Cancer
Burgess, J. T., Croft, L. V., Wallace, N. C., Stephenson, S., Adams, M. N., Ashton, N. W., Solomon, B., O'Byrne, K. J., & Richard, D. J. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.12 · Cited by 15
Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors
Fasano, M., Perri, F., Corte, C. M. D., Liello, R. D., Scarpati, G. D. V., Cascella, M., Ottaiano, A., Ciardiello, F., & Solla, R. (2021) · Biomedicines · doi:10.3390/biomedicines9081045 · Cited by 14
“Moreover, other preclinical and clinical experiences demonstrated that PARPi sensitize cancer cells (including HNSCC) to platinum-based chemotherapy, temozolamide, and topoisomerase inhibitors [49,50].”
BackgroundManguinhas, R., Serra, P., Soares, R. B., Rosell, R., Gil, N., Oliveira, N., & Guedes, R. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021246 · Cited by 10
“Cheng et al. [61] also obtained the same results regarding A549 and HCC827 cells, with A549 cells having the highest expression.”
MethodResultPARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
Mehta, P., & Bothra, S. J. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.002 · Cited by 11
Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
Schmidtova, S., Udvorková, N., Čierna, Z., Horák, S., Kaľavská, K., Chovanec, M., Rojikova, L., Vulevova, M., Kučerová, L., & Mego, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13512 · Cited by 9
Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells
Xiong, T., Chen, X., Wei, H., & Xiao, H. (2015) · Archives of Medical Science · doi:10.5114/aoms.2014.43164 · Cited by 9
“Several studies have confirmed that PARP-1 inhibitors can obviously improve the effects of alkylating agents including cisplatin, cyclophosphamide and oxaliplatin used for chemotherapy [18–21].”
BackgroundPARP Inhibitors and Proteins Interacting with SLX4
Jordheim, L. P. (2023) · Cancers · doi:10.3390/cancers15030997 · Cited by 7
“In another study, veliparib and olaparib were highly active on cells with a low expression of ERCC1 (HCC827 (20% survival at 3 μM olaparib, 10% survival at 50 μM veliparib) and PC9 (10% survival at 3 μM olaparib, 20% survival at 10 μM veliparib)), but less on cells with high ERCC1 expression (A549 (50% survival at 3 μ…”
Cerrato, A., Morra, F., Domenico, I. D., & Celetti, A. (2019) · Cancers · doi:10.3390/cancers12010044 · Cited by 8
Huang, J., Liang, H., Jin, T., & Xie, Z. (2015) · PubMed · Cited by 6
Geenen, J. J. J., Dackus, G. M. H. E., Schouten, P. C., Pluim, D., Marchetti, S., Sonke, G. S., Jóźwiak, K., Huitema, A. D. R., Beijnen, J. H., Schellens, J. H. M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33498 · Cited by 6
“So far, this has only been confirmed in nucleotide excision repair (NER) deficient tumor cell lines, but not in NER proficient tumor cell lines nor PBMCs.37 Furthermore, the REP assay used in our study increased baseline PARP activity in PBMCs on average 121-fold, which probably far outweighs any possible additional e…”
MethodStolzenburg, L. R., Ainsworth, B., Riley-Gillis, B. M., Pakozdi, T., Ammar, A., Ellis, P. A., Wilsbacher, J. L., & Ramathal, C. Y. (2021) · Oncotarget · doi:10.18632/oncotarget.28162 · Cited by 5
“Potentiation of cisplatin by PARP inhibitors has been previously reported in Calu6 and A549 cell lines in vitro and in vivo [15, 23, 24].”
BackgroundAttwa, M. W., Abdelhameed, A. S., Alrabiah, H. K., & Kadi, A. A. (2025) · The Analyst · doi:10.1039/d5an01132a · Cited by 4
Rossi, G., Zullo, L., Cerbone, L., Coco, S., Longo, L., Tagliamento, M., Bello, M. G. D., Boccardo, S., Alama, A., & Genova, C. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1724283 · Cited by 4
Oishi, T., Sasaki, Y., Tong, Y., Chen, L., Onodera, T., Iwasa, S., Udo, E., Furusato, B., Fujimori, H., Imamichi, S., et al. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01001 · Cited by 3
Cao, G., Li, G., Wang, X., Zhang, T., Yao, X., Hou, P., Zhang, J., Guo, X., Wang, J., Xiang, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73271-1 · Cited by 2
Mitra, A., & Ghosh, R. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06600-w · Cited by 4
Xia, M., Ma, S., Wang, W., Chen, D., Chen, M., Wen, C., & Wang, X. (2024) · Acta Chromatographica · doi:10.1556/1326.2024.01230 · Cited by 1
PJ34 prevents cisplatin-induced hair cell loss via inhibition of PARP-1–AIF parthanatos
Nong, H., Zhang, X., Yuan, Y., Zhang, J., Zhao, J., & Cao, Z. (2025) · Biomolecules and Biomedicine · doi:10.17305/bb.2025.12533 · Cited by 3
“Inhibiting PARP-1 leads to decreased DNA repair function and is considered an important mechanism for alleviating cisplatin resistance in cancer cells [10].”
Chen, Z., Yang, F., Yu, Y., Chen, J., Ye, J., & Ding, Y. (2025) · Orthopaedic Surgery · doi:10.1111/os.70211 · Cited by 1
“While previous studies have documented PARP1 involvement in various malignancies [23–25] and inflammatory conditions [26–28], our work demonstrates its progressive upregulation during TiPs-induced macrophage activation, thereby supporting its specific contribution to the pathogenesis of aseptic…”
Swisher, E. M., Aghajanian, C. A., O’Malley, D. M., Fleming, G. F., Kaufmann, S. H., Levine, D. A., Birrer, M. J., Moore, K. N., Spirtos, N. M., Shahin, M. S., et al. (2022) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000827620.82650.68 · Cited by 1
Grdović, N., Tolić, A., Jovanović, M., Rajić, J., Đorđević, M., Stojanović, M., Hadžić, S., Marković, T., Sarić, A., Dinić, S., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1677261 · Cited by 1
Customizing Chemotherapy in Thoracic Malignancies based on ERCC1 Expression
S⊘rensen, J. B., Jakobsen, J. N., Zimling, Z. G., Wallerek, S., & Vilmar, A. C. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.30
Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy
Gentile, F., Cros‐Perrial, E., & Jordheim, L. P. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189408
Lapke, N., Chen, C.-H., Chang, T.-C., Chao, A., Lu, Y.-J., Lai, C.-H., Tan, K. T., Chen, H.-C., Lu, H.-Y., & Chen, S.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14538774
Lapke, N., Chen, C.-H., Chang, T.-C., Chao, A., Lu, Y.-J., Lai, C.-H., Tan, K. T., Chen, H.-C., Lu, H.-Y., & Chen, S.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14538777
Lapke, N., Chen, C.-H., Chang, T.-C., Chao, A., Lu, Y.-J., Lai, C.-H., Tan, K. T., Chen, H.-C., Lu, H.-Y., & Chen, S.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14538789
Lapke, N., Chen, C.-H., Chang, T.-C., Chao, A., Lu, Y.-J., Lai, C.-H., Tan, K. T., Chen, H.-C., Lu, H.-Y., & Chen, S.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14538765
Lapke, N., Chen, C.-H., Chang, T.-C., Chao, A., Lu, Y.-J., Lai, C.-H., Tan, K. T., Chen, H.-C., Lu, H.-Y., & Chen, S.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14538786
Lapke, N., Chen, C.-H., Chang, T.-C., Chao, A., Lu, Y.-J., Lai, C.-H., Tan, K. T., Chen, H.-C., Lu, H.-Y., & Chen, S.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14538762
Lapke, N., Chen, C.-H., Chang, T.-C., Chao, A., Lu, Y.-J., Lai, C.-H., Tan, K. T., Chen, H.-C., Lu, H.-Y., & Chen, S.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14538792
Postel-Vinay, S. C. (2013) · theses.fr (ABES) · doi:10.70675/dfafa49bz0bfbz4dfcz9d21zc773c2c95c05
“An independent study performed at the same time as this thesis reported in parallel that PARP inhibitors could synergize with cisplatin in ERCC1-low NSCLC cells and not in ERCC1-high cells, suggesting that ERCC1-deficiency could at least partly drive both platinum and PARP inhibitor sensitivity (Cheng et al., 2013).”
Création de biomarqueurs à visée pronostique et prédictive dans les cancers broncho-pulmonaires.
Adam, J. (2015) · theses.fr (ABES) · doi:10.70675/53409899z91c0z4b6fzae62z8ed735b6e2c3
Metadata
- Authors
- Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B.
- Affiliations
- NewYork–Presbyterian Hospital (US)
- Mount Sinai Hospital (US)
- Columbia University Irving Medical Center (US)
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-28
- Volume
- 34
- Issue
- 4
- Pages
- 739-749
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- PMC
- PMC3616665
- OpenAlex
- W2135915034
- Cited by
- 99
- References
- 50
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 18 · 2020: 4 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 15 · 2014: 8 · 2013: 3
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Carcinogenesis (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health (5k12ca132783-12)
- National Cancer Institute (CA 130536, 5K12CA132783-04, R01CA130536)
- National Institute of General Medical Sciences (R01GM079107, GM079107)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- PARP inhibition, cisplatin, ERCC1, non-small cell lung cancer, olaparib, veliparib, nucleotide excision repair, drug synergy, DNA double-strand breaks, G2/M cell cycle arrest, apoptosis, tumor markers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Checkpoint Kinase 1, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carcinoma, Non-Small-Cell Lung, Cisplatin, DNA-Binding Proteins, Drug Synergism, Endonucleases, Humans, Lung Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerases, Protein Kinases, Apoptosis, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, DNA Breaks, Double-Stranded, G2 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.